Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Broad Enough? Sponsors Pleased With Narrower Praluent Label

This article was originally published in The Pink Sheet Daily

Executive Summary

Indication for cholesterol-lowering drug is narrower than Sanofi and Regeneron originally sought, but firms still see it as broad. Target patient population is estimated at 8-10 million patients, but sponsors are quick to say the number of actual users will be funneled down.

You may also be interested in...



Praluent Injunction Goes Unmentioned At PCSK9 Patent Case Appeal

Three-judge US federal appellate panel focuses on evidentiary rulings and patent validity in the dispute between Repatha marketer Amgen and Sanofi/Regeneron; lower court’s permanent injunction barring sales of Praluent did not come up at oral arguments.

Can Cholesterol Drug Sponsors Make The Case For Statin Intolerance?

Amgen's FOURIER outcomes study of Repatha supports LDL-lowering in high risk patients, but price may have to come down dramatically to spur wide use of the PCSK9 inhibitors with the subjective condition of statin intolerance.

Sanofi’s Praluent Closes Gap On Repatha In Europe, As GSK Gets Green Light For World’s First Malaria Vaccine

Europe’s CHMP grants positive opinions for Sanofi’s Praluent and GSK’s not-for-profit malaria vaccine Mosquirix at July meeting; other products recommended include Shire’s Intuniv, Merck’s Zerbaxa, Basilea’s Cresemba and Keryx’s Fexeric.

Topics

Related Companies

UsernamePublicRestriction

Register

PS078733

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel